English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Alzheimer's disease (AD) is a neurogenerative disorder that had no effective treatment until a few years ago. Many studies published during the past 20 years showed that the disease is associated with the disruption of brain systems that use acetilcholine. These findings shaped the development of the cholinergic treatment strategies for AD. The cholinesterase inhibitors were the first class of drugs to show positive results in double-blind placebo controlled studies for the treatment of AD. This paper reviews efficacy and safety studies of tacrine, donepezil, rivastigmine, and metrifonate in patients with AD. Factors that may interfere with patients' response to treatment are also discussed, as well as the limitations associated with the use of this class of drugs.

Tratamento da doença de Alzheimer: avaliação crítica sobre o uso de anticolinesterásicos